Publications
Original Article
Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine
Cancer Vaccines
2001
Authors:
Knutson KL, Disis ML
Journal:
Clinical Breast Cancer
Volume:
2(1)
Page:
73-79
Pubmed:
Original Article
Identification of T helper epitopes from prostatic acid phosphatase
Cancer Vaccines
2001
Authors:
McNeel DG, Nguyen LD, Disis ML
Journal:
Cancer Research
Volume:
61(13)
Page:
5161-7
Pubmed:
Original Article
HER2/neu peptide-based vaccines, with GM-CSF as an adjuvant, in patients with advanced-stage HER2/neu-expressing cancers
Cancer Vaccines
2000
Authors:
Schffman K and Disis ML
Journal:
Clinical Lung Cancer
Volume:
2(1)
Page:
74-7
Pubmed:
Original Article
Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer
Cancer Vaccines
2000
Authors:
McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH, and Disis ML
Journal:
Journal of Urology
Volume:
164(5)
Page:
1825-9
Pubmed:
Original Article
Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T cell responses, despite upregulation of MHC class II expression
Tumor Microenvironment
2000
Authors:
Bernhard H, Huseby ES, Hand SL, Lohmann M, Batten WY, Disis ML, Gralow JR, Meyer zum Bruschenfelde KH, Ohlen C and Cheever MA
Journal:
Immunobiology
Volume:
201(5)
Page:
568-82
Pubmed:
Original Article
Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer
Cancer Vaccines
2000
Authors:
Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG
Journal:
Breast Cancer Research and Treatment
Volume:
62(3)
Page:
245-52
Pubmed:
Original Article
Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization
Cancer Vaccines
2000
Authors:
Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K and Knutson KL
Journal:
Clinical Cancer Research
Volume:
6(4)
Page:
1347-50
Pubmed:
Original Article
Immunity to WT1 in the animal model and in patients with acute myeloid leukemia
Cancer Vaccines
2000
Authors:
Gaiger A, Reese V, Disis ML and Cheever MA
Journal:
Blood
Volume:
96(4)
Page:
1480-9
Pubmed:
Original Article
Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor
Clinical Trials
1999
Authors:
McNeel DG, Schiffman K, Disis ML
Journal:
Blood
Volume:
93(8)
Page:
2653-9
Pubmed:
Original Article
Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
Cancer Vaccines
1999
Authors:
Disis ML, Grabstein KH, Sleath PR and Cheever MA
Journal:
Clinical Cancer Research
Volume:
5(6)
Page:
1289-97
Pubmed: